APP and nervous system disorder: These observations have been supported and extended by myriad reports over the intervening years (Ryan et al., 2013; Hefter et al., 2016) and has generated suggestions that the promotion of α-secretase cleavage of APP and increasing APPsα levels could be a therapeutic strategy for the treatment of Alzheimer’s disease (AD; Turner et al., 2003; Ring et al., 2007; Postina, 2012; Hick et al., 2015; Fol et al., 2016; Habib et al., 2016) and possibly other neurological disorders.